News and Events
Study sheds light on diversity of study participants at CCR
Diversity in clinical trials is critical for understanding how well a treatment may work in different populations. A new study describes representation based on sex, age and ethnicity in clinical trials done at CCR.
Read MoreNew T-cell therapy shrinks solid tumors in early-phase clinical trial
Trial results show that engineered T cells can effectively target mesothelin, a protein found on many solid tumors.
Read MoreStudies of an experimental ovarian cancer therapy identify a biomarker of treatment response
A new biomarker may identify patients who can benefit from drugs that inhibit CHK1 after their ovarian cancer has become resistant to PARP inhibitors.
Read MoreRemembering Miranda Leah Hanson-Baseler, an indomitable immunologist
Faced with a uterine sarcoma diagnosis at just 24, Miranda Leah Hanson-Baseler persevered through treatments for 17 years.
Read MoreNew analysis reveals potential effective drug combinations for treating lung cancer
Researchers compared more than 5,000 drug combinations in lung cancer cells, the results of which point to combinations that may be particularly effective in combating cancer in humans.
Read MoreAligned Blog: Mentoring Across Difference
For many people, navigating higher education and entering the workforce can be challenging but having a good mentor, especially one who considers how your background impacts your lived experience, can make a difference. In this blog, the Office of Equity and Inclusion's newest team member, Sonia A. Garcia, Ph.D., writes about her experience navigating through a Ph.D. program as a first-generation Latina student and the importance of mentoring across difference.
Read MoreCells’ decision to divide is reversible
Surprising findings show that cells that are preparing to divide can return to a resting state if they lose growth signals, even after they have passed what was previously thought to be a point of no return.
Read MoreDrug combination provides a one-two punch attack against colorectal cancer
Researchers have identified a drug that, when combined with TOP1 inhibitors, results in improved efficacy in human colorectal cancer models — a finding that may apply to other cancers treated with TOP1 inhibitors. The results also yield important insights into our basic understanding of DNA replication and repair.
Read MoreClinical trial researching immunotherapy for tumors with specific genetic deficiencies
Mary Frances Wedekind Malone, D.O., Assistant Research Physician in the Pediatric Oncology Branch, is researching immunotherapy for SMARCB1- and SMARCA4-deficient tumors.
Read MoreClinical trial researching therapy for recurrent respiratory papillomatosis
Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is leading a trial researching drug therapy for recurrent respiratory papillomatosis.
Read MoreClinical trial researching T-cell therapy for epithelial cancers
Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is leading a trial researching T-cell therapy for gastric, breast, cervical, lung and other types of epithelial cancers.
Read More